Get the Stockscreener App
11.41
0.80%
0.09
Pre-market:
11.28
-0.13
-1.14%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Viatris Inc stock is traded at $11.41, with a volume of 4.16M.
It is up +0.80% in the last 24 hours and up +2.52% over the past month.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
See More
Previous Close:
$11.32
Open:
$11.36
24h Volume:
4.16M
Relative Volume:
0.52
Market Cap:
$13.62B
Revenue:
$15.24B
Net Income/Loss:
$-646.50M
P/E Ratio:
7.4575
EPS:
1.53
Net Cash Flow:
$1.88B
1W Performance:
-0.52%
1M Performance:
+2.52%
6M Performance:
-3.47%
1Y Performance:
+18.12%
1-Day Range:
$11.29
$11.46
1-Week Range:
$11.23
$11.65
52-Week Range:
$8.74
$13.62
Viatris Inc Stock (VTRS) Company Profile
Name
Viatris Inc
Sector
Phone
(724) 514-1465
Address
1000 MYLAN BOULEVARD, CANONSBURG
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-23-23 | Downgrade | Barclays | Equal Weight → Underweight |
| Apr-24-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-17-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-27-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-10-22 | Upgrade | UBS | Sell → Neutral |
| Nov-08-22 | Upgrade | Piper Sandler | Underweight → Neutral |
| Oct-21-22 | Resumed | Jefferies | Hold |
| Jun-14-22 | Initiated | UBS | Sell |
| May-10-22 | Downgrade | Piper Sandler | Neutral → Underweight |
| Mar-01-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-01-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-15-21 | Initiated | Citigroup | Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Mar-08-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-26-21 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jan-05-21 | Initiated | Argus | Hold |
| Dec-14-20 | Initiated | Bernstein | Mkt Perform |
View All
Viatris Inc Stock (VTRS) Latest News
Viatris reports positive results for EFFEXOR in Japan GAD study - Investing.com
Viatris reports positive results for EFFEXOR in Japan GAD study By Investing.com - Investing.com UK
Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD) - StockTitan
Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row - StockTitan
Viatris 2023 Sustainability Report: Expanding Contractor Training - CSRwire.com
Is Viatris Inc. (NASDAQ:VTRS) The Best NASDAQ Stock Under $20? - Insider Monkey
Is Viatris Inc. (NASDAQ:VTRS) The Best NASDAQ Stock Under $20? - Yahoo Finance
Novo Nordisk settles US patent fight with Viatris over Ozempic - Reuters
Viatris 2023 Sustainability Report: Expanding Contractor Training - Yahoo Finance
Insomnia Drug Market to Witness Huge Growth by 2024 | Sanofi, Lundbeck, Viatris - openPR
(VTRS) On The My Stocks Page - Stock Traders Daily
Naloxone Market Set to Witness Significant Growth by 2024-2031:Akorn,Inc, Kaleo,Inc., Pfizer Inc, Viatris - EIN News
Amazon.com Inc. stock outperforms competitors despite losses on the day - MSN
Is Viatris Inc. (VTRS) the Best Stock Under $15 To Buy Now? - Yahoo Finance
Viatris's SWOT analysis: generic drug maker's stock faces challenges amid growth - Investing.com India
Viatris's SWOT analysis: generic drug maker's stock faces challenges amid growth - Investing.com
Viatris launches (Pr)Viagra® ODF in Canada: a new oral dissolving film form of the erectile dysfunction treatment - Yahoo Finance
Viatris to close Cork plant with 200 jobs impacted - MSN
Access at scale for sustainable healthcare development - Vietnam Investment Review
Piper Sandler maintains Neutral rating on Viatris stock with steady price target - Investing.com
Piper Sandler maintains Neutral rating on Viatris stock with steady price target - Investing.com India
Viatris delivering high-quality, accessible, and sustainable healthcare solutions - Vietnam Investment Review
Anti-retroviral Drugs Market to hit USD 42.5 billion by 2032, says Global Market Insights Inc. - GlobeNewswire Inc.
Sustainable dynamics for improved patient access - Vietnam Investment Review
XTX Topco Ltd Boosts Stake in Virtus Investment Partners, Inc. (NASDAQ:VRTS) - Defense World
Ventyx gets $27 million investment from Sanofi - The Pharma Letter
Viatris Inc [VTRS] Stock trading around $11.39 per share: What’s Next? - The DBT News
Sanofi investment in Ventyx shows VTX3232 interest, says H.C. Wainwright - TipRanks
Barclays gives an Equal weight recommendation for Vertex Pharmaceuticals, Inc. (VRTX) - Knox Daily
Viatris Gets Shareholders' Biosimilars Class Action Thrown Out - Bloomberg Law
Viatris Inc (VTRS) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Is Viatris Stock Underperforming The Dow? - Barchart
(VTRS) Technical Pivots with Risk Controls - Stock Traders Daily
Fidelis Capital Partners LLC Increases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Legacy Financial Advisors Inc. Increases Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - Defense World
GM Advisory Group LLC Sells 31 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - Defense World
Viatris Inc (VTRS) Shares Down 5.34% on Sep 20 - GuruFocus.com
In Europe, Packaging Site Takes Flight as a Bird-Friendly Workplace - CSRwire.com
Viatris 2023 Sustainability Report: Health and Safety in the Workplace - CSRwire.com
General Anesthesia Drugs Market Generated Opportunities, - openPR
Jupiter Endovascular treats first patients with Vertex system in SPIRARE I study - Medical Device Network
Viatris 2023 Sustainability Report: Health And Safety In The Workplace - MENAFN.COM
In Europe, Packaging Site Takes Flight as a Bird-Friendly Workplace - AccessWire
In Europe, Packaging Site Takes Flight as a Bird-Friendly Workplace - Yahoo Finance
Jupiter Endovascular announces first cases with Vertex pulmonary embolectomy system - Mass Device
Viatris 2023 Sustainability Report: Health and Safety in the Workplace - AccessWire
Viatris 2023 Sustainability Report: Health and Safety in the Workplace - StockTitan
Viatris 2023 Sustainability Report: Health and Safety in the Workplace - ReportAlert.info
China Mesalazine Market Projected To Witness Substantial Growth, 2024-2031:AbbVie Inc, GSK Plc, Novartis AG, - EIN News
Victoria’s Secret & Co. (NYSE:VSCO) Upgraded to Equal Weight at Barclays - Defense World
VF (NYSE:VFC) Upgraded to Overweight by Barclays - Defense World
Viatris Inc Stock (VTRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.01%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):